glp-1-based therapy GLP-1 Receptor Agonists as Treatments for Type 2 Diabetes GLP-1 Therapy for Patients with

This was observed through a decrease in the levels of the proteins that play a role in the synthesis of steroid hormones in the ovaries, such as the steroidogenic acute regulatory protein

doi: 10.1097/NPT.0b013e3181dde6d8

The date of discovery may be related to when the link between the drug and the condition was established

Ozempic (Semaglutide): As a GLP-1 agonist, Ozempic works by slowing gastric emptying, which can commonly lead to side effects such as nausea, vomiting, diarrhea, and constipation

Caseinolytic protease B (ClpB), a component protein of E

Results indicate that DA-JC1 reduces neuroinflammation by inhibiting the proliferation of astrocytes and microglia in the substantia nigra, and mitigates the damage of toxic substances MPTP to midbrain dopaminergic neurons and fibers by promoting the expression of BDNF, phosphorylation of Akt in the PI3K/Akt signaling pathway, downregulating the pro-apoptotic protein Bax, and upregulating the anti-apoptotic protein Bcl2 (109, 110)